Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eliminate "Drug Lag" at Initiative of Politicians: Mr Sekiguchi
November 2, 2009
- DSP Completes Acquisition of Sepracor Inc.
November 2, 2009
- Astellas, IBL Discontinue Development of ASK8007 as Anti-RA Drug
November 2, 2009
- Pfizer Completes Acquisition of Wyeth
November 2, 2009
- Kyowa Kirin to Apply for KW-0761 Hopefully in 2011
November 2, 2009
- Roche to Strengthen Partnering in Japan: Mr McCracken
November 2, 2009
- REGULATORY NEWS IN BRIEF
November 2, 2009
- EP-Mint to Acquire Sogo SMO: EPS
November 2, 2009
- Lawmakers to Have Stronger Influence on Medical Fees
November 2, 2009
- Incretin Therapy Suitable for Japanese Patients with Diabetes: Dr Seino
October 26, 2009
- REGULATORY NEWS IN BRIEF
October 26, 2009
- Biogen Idec Japan Aims at 50% Share in Market for IFN-b
October 26, 2009
- Shionogi Allies with UK Universities, Bioventures for Drug Discovery
October 26, 2009
- Rasilez May Become Blockbuster: T. Rosenberg, Novartis
October 26, 2009
- Life Science Degrades to 2nd Place in Priority Science and Technology Ranking
October 26, 2009
- Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
October 26, 2009
- R＆D NEWS IN BRIEF
October 26, 2009
- Nat'l Univ. Hospitals Plans to Start Joint Purchasing in FY2010
October 26, 2009
- Hokkaido Univ. Hospital to Increase Direct Purchase of Drugs
October 26, 2009
- Cravit Remains No. 1 on Both HP, GP Markets: Rep Track Survey
October 26, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…